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Abhik Seal 
RANDOM WALK APPLIED TO HETEROGENOUS DRUG-TARGET 
NETWORKS FOR PREDICTING BIOLOGICAL OUTCOMES 
Prediction of unknown drug target interactions from bioassay data is 
critical not only for the understanding of various interactions but also 
crucial for the development of new drugs and repurposing of old ones. 
Conventional methods for prediction of such interactions can be divided 
into 2D based and 3D based methods. 3D methods are more CPU 
expensive and require more manual interpretation whereas 2D methods 
are actually fast methods like machine learning and similarity search 
which use chemical fingerprints. One of the problems of using 
traditional machine learning based method to predict drug-target pairs 
is that it requires a labeled information of true and false interactions. 
One of the major problems of supervised learning methods is selection 
on negative samples. Unknown drug target interactions are regarded as 
false interactions, which may influence the predictive accuracy of the 
model. To overcome this problem network based methods has become an 
effective tool in predicting the drug target interactions overcoming the 
negative sampling problem. 
In this dissertation study, I will describe traditional machine learning 
methods and 3D methods of pharmacophore modeling for drug target 
prediction and will show how these methods work in a drug discovery 
scenario. I will then introduce a new framework for drug target prediction 
based on bipartite networks of drug target relations known as Random 
Walk with Restart (RWR). RWR integrates various networks including drug–
drug similarity networks, protein-protein similarity networks and drug-
target interaction networks into a heterogeneous network that is capable 
of predicting novel drug-target relations. I will describe how chemical 
features for measuring drug-drug similarity do not affect performance in 
predicting interactions and further show the performance of RWR using 
an external dataset from ChEMBL database. I will describe about further 
implementations of RWR approach into multilayered networks consisting of 
biological data like diseases, tissue based gene expression data, protein-
complexes and metabolic pathways to predict associations between 
	 vi	
human diseases and metabolic pathways which are very crucial in drug 
discovery. I have further developed a software tool package netpredictor in 
R (standalone and the web) for unipartite and bipartite networks and 
implemented network-based predictive algorithms and network properties 
for drug-target prediction. This package will be described. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
1.1 BACKGROUND 
 
Despite many advances in the past decades, drug discovery is still a 
costly and time-consuming process. In recent years the rate of successful 
drug developed has decreased [1, 2] and in this light new indications for 
existing and abandoned drugs showing some promise [3]. Such a new 
strategy is called drug-repurposing [4]. Drug repositioning is also 
promising for shelved compounds because they failed in clinical trials 
and were not further investigated. These drugs could be quickly 
marketed for new indications [5, 6], thus reducing the attrition rates. 
These new interactions can also be useful for understanding causes of 
adverse effects of existing drugs. Traditional drug discovery follows a 
reductionist’s approach, where a large complex system is divided into 
multiple parts. For example, a medicinal chemist assumes that ligands 
and their structure have sufficient information to provide an 
understanding of the behavior of target interaction and pharmacology. 
Connecting cellular components to tissue or organ-level based on 
gene expression data helps to identify new targets. Similarly 
identifying disease-based pathways requires gene expression data 
from tissues/organs, which forms proteins complexes, which 
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connects metabolic pathway. This is because  different diseases 
like alzheimer’s, ulcers, ischemic heart disease and cirrhosis 
occurs which occurs in different tissues like brain, stomach, heart 
and liver have different level of protein expression respectively. 
Actions of drug are changing the way it was use to described earlier 
in figure 1.1. Today it is clear that an adverse event or a 
pharmacological event occurs due to coordination of number of 
biological components in the system describe in figure 1.2. Interactions 
between the different components and influences from the environment, 
give rise to network behavior, which are absent in the isolated 
components [7].  
  
 
  
 
 
Traditional approaches for drug target interaction prediction are generally 
based on virtual screening. Virtual screening or insilco screening is the use 
of high performance computing environments to screen compounds for drug 
candidates, which is classified into ligand-based and target-based 
approaches described in the next section. 
Off	-	target	
on-	target	
				Drug	
Therapeutic	
effect	
Adverse	
Effect	
                 Figure 1.1 Classic drug target pharmacology [95] 
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Ligand-based approaches screen candidate compounds or ligands to 
predict whether they interact with a given target based on the 
assumption that similar drugs interact with the same target. The 
similarity of two drugs is measured in different ways with respect to 
different aspects. Other than comparing drugs according to their 
chemical structures [8], side effect has also been used to measure the 
similarity between drugs [9]. Assuming that similar targets bind to the 
same ligand, target-based approaches, on the other hand, compare 
proteins to predict whether they bind to the given ligand, or whether they 
are the targets of the given drug or compound. More specifically, for a 
given drug, new targets are identified by comparing candidate proteins to 
the known targets of this drug with respect to certain descriptors such 
as amino acid sequence, binding sites, or ligands that bind to them. 
Supervised machine learning using ligand based methods [10–13] drug-
      Figure 1.2 Network view of drug action idea taken from Berger and 
Iyenger [95]  
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target pairs are labeled as positive or negative samples according to 
confirmed interaction between corresponding drug and target pairs.  The 
selection of negative samples is a common problem of all the supervised 
learning methods, as unknown drug–target interactions have been assumed 
as negative samples in the supervised learning methods. Selection of 
negative samples largely influences the predictive accuracy.  It’s difficult to 
decide the correct combination of datasets and fingerprints to prioritize 
targets. Selection of molecular descriptors plays a crucial role in drug 
discovery. Several fingerprints such as path based fingerprints (TT ad AP), 
substructure based fingerprints (MACCS and pubchem), circular fingerprints 
(ECFP, FCFP, PHFP) are used for prioritization of compounds. Performance of 
the fingerprints depends on different datasets. Mostly circular and path 
based fingerprints have high performance in retrieving active compounds 
than other types of fingerprints [95-98]. The random walk method with 
proper optimization of parameters discussed in chapter 2 of the dissertation 
will show how one can use any kind chemical fingerprints to get similar 
results for target prioritization. The random walk based method described in 
this dissertation overcomes the limitation for negative sampling problem and 
also it doesn’t require the labeled information of drug–target interaction. One 
can give unlabeled information of drugs and after computation the algorithm 
predicts the interactions.  In chapter four, another problem we are trying to 
address if the method of random walk with restart can be implemented using 
multipartite networks, which integrates a heterogeneous network structure 
contains more 3 kinds of networks. Chapter 5 discusses about the 
netpredictor standalone and web software which computes the network 
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properties and computes four different algorithms HeatS, network based 
inference (NBI), random walk with restart (RWR) and netcombo (NBI+RWR). 
The method, which is implemented in this dissertation, falls under ligand-
based approach. 
The next section describes about the traditional types of virtual screening. 
1.2 VIRTUAL SCREENING STRATEGIES 
 
Computational ligand (compound) design is divided into two strategies,  
ligand based and target based drug design that can be used together or 
independently. Ligand based drug design relies on set of active and 
inactive ligands where no 3D structural information of the target is 
available.  Structure based drug design is applicable when the target’s 
3D information is available along with the binding site information. Figure 1.3 
shows how virtual screening in classified. 
Depending upon structural and Bioactvity data available: 
•  One or more actives molecule known perform similarity searching. 
•  Several active known try to identify a common 3D pharmacophore and   
   then do 3D database search. 
•  Reasonable number of active and inactive known train a machine     
    learning model. 
•  3D structure of protein known use protein ligand docking. 
People working in pharmaceutical industry does not follow a specific route 
whatever information they have follow a hybrid of methods. Figure 1.4 shows 
how both the ligand based and structured based design can be integrated. 
While designing new ligands one starts with a database of chemical structures 
	 6	
and performs a search for similar structures based on 3D shape or 2D chemical 
fingerprints. Then if a 3D crystallographic protein structure is avail- able with a 
ligand attached then one can design a structure-based pharmacophore [14, 15]. 
If the 3D protein structure is missing one can go for the ligand based 
pharmacophore and then select some potential lead compounds. If there exists 
a 3D structure then one can use 3D docking tool to find the pattern of 
interactions. 
 
 
 
 
 
 
 
 
 
 
 
                    Figure 1.3: Diagram showing Virtual screening pathways. 
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                    Figure 1.4: Diagram showing  hybrid Virtual screening  
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1.3 OVERVIEW OF THE STUDY 
 
1.3.1 RANDOM WALK WITH RESTART ON DRUG TARGET       
          HETEROGENOUS  NETWORK                               
Predicting novel drug–target associations is important not only for 
developing new drugs, but also for furthering biological knowledge by 
understanding how drugs work and their modes of action. Network based 
description and analysis not only give a systems-level understanding of 
drug action and disease complexity, but can also help to improve the 
efficiency of drug design. As more data about drugs, targets, and their 
interactions becomes available, computational approaches have become an 
indispensible part of drug target association discovery. In this chapter we 
apply random walk with restart (RWR) method to a heterogeneous network 
of drugs and targets compiled from drugbank database and investigate the 
performance of the methods under parameter variation and choice of 
chemical fingerprint methods. 
Random walk is a useful mathematical framework that provides a 
systematic way to measure importance of nodes in a network. The most 
widely known is the PageRank algorithm [29]. PageRank, developed for 
ranking web pages, measures page clicks of hypothetical web surfers who 
randomly click hyperlinks in the network of webpages. Since it is possible 
for the surfer to be trapped in a dead-end webpage that does not have 
any connection to the main network, at each time step the surfer may 
jump to a random webpage with a probability c. Interestingly, this 
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formulation also provides a simple way to define a random walk-based 
“distance” from a node a (or a set of nodes) to every other node, namely by 
allowing the random walkers to jump only to the source node a (or the 
source set of nodes) and restart from there. As a result, it is more likely 
to find the random walker at the vicinity of the source node than at a 
distant part of the network, and thus we are able to estimate the 
relevance (closeness) of each node with respect to the source node. The 
prediction method applies this idea to identify drugs and targets that are 
relevant to a set given set of drugs and targets. 
Consider an undirected, unweighted network G = (V, E), where  V     is the 
set of nodes and E is the set of links.  For each pair of nodes a,bV we 
can assign a proximity score by executing the following procedure: 
– we start a random walker from a. 
– At each time step, with the probability 1 - c, the walker walks to 
one of the neighbors, b, according to the transition value matrix !"# =	&'()'  where *"# is the adjacency matrix of the network and (*"#	equals 1  if 
node a and b are connected, 0 otherwise) +" denotes  the degree of a. 
– With probability c , the walker goes back to a. 
– After many time steps the probability of finding the random walker 
at node x converges to the steady-state probability which is our 
proximity score *"→-.  
 
The random walk with restart, whose updating equation is shown as 
follows: 
                                            pt+1  = (1-c)WT pt + cp0                              (1.1) 
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Keep updating p until convergence; the stationary distribution vector p 
can meet, 
                                       pt = (1 − c)(I − cW T )−1p0                   (1.2)  
We show that choice of chemical fingerprint does not affect the 
performance of the method when the parameters are tuned to optimal 
values. We use a subset of the ChEMBL15 dataset that contains 2,763 
associations between 544 drugs and 467 target proteins to evaluate our 
method, and we extracted datasets of bioactivity ≤ 1 and ≤ 10 µM activity 
cutoff. For 1 µM bioactivity cutoff, we find that our method can correctly 
predict nearly 47, 55, 60% of the given drug–target interactions in the test 
dataset having more than 0, 1, 2 drug target relations for ChEMBL 1 µM 
dataset in top 50 rank positions. For 10 µM bioactivity cutoff, we find that 
our method can correctly predict nearly 32.4, 34.8, 35.3% of the given 
drug–target interactions in the test dataset having more than 0, 1, 2 
drug target relations for ChEMBL 1 µM dataset in top 50 rank positions. 
We further examine the associations between 110 popular top selling 
drugs in 2012 and 3,519 targets and find the top ten targets for each drug. 
We demonstrate the effectiveness and promise of the approach—RWR on 
heterogeneous networks using chemical features—for identifying novel drug 
target interactions and investigate the performance. 
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1.3.2 DISEASE TO PATHWAY PREDICTION USING RANDOM WALK    
         WITH RESTART 
Besides identifying individual disease related genes, associating pathways 
to human inherited diseases is of great importance, because the disease 
conditions arise from the cooperative behavior of multiple proteins in 
protein interaction network which forms protein complexes
and plays an important role in disease pathways. Integrating pathway 
level data would play a key role in understanding mechanism of action 
of diseases. It is well known that genes within a cell do not function 
alone. They interact with each other to form complexes and form 
pathways to carry out biological functions. Also identifying the pathways 
could help in design and repurpose drugs of similar or unknown diseases 
with similar symptoms. Here in this chapter I have designed a system, 
which is composed, of disease data connected to 60 different tissues [30] 
based protein interaction network which is developed from the 
expression profiles of human proteome, and associate them with protein 
complexes to biological pathways. We propose a random walk based 
model to query a specific disease, which then loads the disease tissue, 
based protein-protein interaction network and its pro- teins complexes 
and identifies biological pathways associated with the disease. With several 
leave-one out validations we optimized the network to achieve best results. 
The results can be used to predict unknown pathways associated with 
the disease and would help in drug repurposing related to those 
pathways. 
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1.3.3 NETPREDICTOR SOFTWARE FOR NETWORK BASED   
         PREDICTION     
Searching missing associations between drug and targets is valuable to 
understand polypharmacology and as well as understand off-target 
mediated effects of chemical compounds in biological systems. Traditional 
machine learning algorithms like Naive Bayes, SVM and Random Forest 
have been successfully applied to predict drug target relations. However, 
using supervised machine learning method we need to label the drug- 
target pairs with negative and positive samples to understand the known 
relation between drug and target is known or not. Therefore, unknown 
drug target relations are regarded as negative and im   proper negative 
sample selection can largely affect the predictive accuracy. Network based 
models tries to avoid these kind of issues on negative sampling biases.
Cheng [31] developed a technique based on Network Based Inference 
(NBI) and developed three supervised methods on drug similarity, target 
similarity and network topology and showed superior performance of 
network topology based method. Alaimo [32] have extended Cheng’s 
method of network model to integrate Chemical and target similarity into 
account to show that the performance of the method superior to Cheng’s 
model. Chen [33] and Seal [27] have used random walk with restart 
(RWR) based method to predict drug target interactions on a 
heterogeneous network made up of drug-drug similarity, protein-protein 
similarity and bipartite graph between drugs and targets. Seal [27] have 
extended the method by optimizing a parameter η, which showed that the 
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performance of RWR is independent of the choice of using Chemical 
fingerprint features. The netpredictor package provides the implements 
the Random walk with Restart algorithm in a biparite and unipartie 
network and also implements the Alaimo’s algorithm of network-based 
inference. The algorithm also implements method to predict the 
unknown relations and the relations and perform permutations tests on 
the given network for predicted values. 
1.4    RELATED WORK 
 
Random walk with restart is being applied to many bioinformatics 
related problems in prioritization of diseases based on protein - protein 
interaction network [34] non-coding RNAs [35]. Campillos etal. [36] 
established a method using drug side-effect similarity to find diverse 
compounds binding a similar target. Cheng etal [37] developed three 
super- vised inference models namely drug-based similarity inference 
(DBSI), target-based similarity inference (TBSI) and network-based 
inference (NBI) to predict drug target interactions. DBSI and TBSI 
depends on chemical structure similarity and target sequence sim- 
ilarity, respectively, whereas NBI is only based on drug–target bipartite 
network topology similarity. Yamanishi [38] proposed a bipartite graph 
learning method to predict drug-target interactions by integrating
the chemical structure information, the sequence similarity information 
and known drug-target information into a supervised kernel-regression 
method to predict new drug-target interactions. He further proposed a 
pharmacological similarity based network [39] learning method where he 
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integrated pharmacological similarity into supervised bipartite graph 
model to identify new drug-target interactions. 
1.5    CONCLUSION 	
In this dissertation we are using network based random walked with restart to 
predict biological outcomes.  One of the outcomes is prediction of drug target 
interactions and another one is prediction of metabolic pathways of diseases 
using tissue-based protein – protein interaction network and protein complexes 
information network. The paper from Chen etal described the way to performing 
RWR in bipartite network with chem-biological data. However there were certain 
limitations on that work.  The paper focused on prediction of drug targets based 
on certain groups of proteins like GPCR, Ion Channels, Enzymes and Nuclear 
Receptor. However, it didn’t consider the off class interactions of drugs. In order 
to check the off class cross prediction we created a full data of 3519 proteins 
and then we predicted the off class interactions with relative good performance. 
Testing drug target interactions at different activity endpoints is also very 
crucial in understanding lead compounds. We tested our methods with 
ChEMBL data at 10000 μM and 1000 μM and it showed very good performance.  
Another important fact that came out of this dissertation is we know chemical 
fingerprints plays a crucial role in prioritization of targets. We have optimized 
parameter η to 0.01, which controls the importance of two kinds of nodes, i.e. 
drug node and target node. When this parameter is optimized we can control 
the use of chemical similarity matrices. It means that whatever similarity 
matrices you use one can exactly same prioritization results. This will help in 
using open public version of fingerprints than commercial versions. Also Chen 
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etal didn’t release any kind of codes for there computation we have developed a 
standalone and web based application of the random walk with restart and 
network based inference methods for prioritization of targets and is freely 
available. 
Other than prioritization of drug targets, with the random walk framework can 
also be used to integrate multi partite networks and predict outcomes. We 
wanted to predict disease based metabolic pathways. Diseases occur in different 
tissues and organs also depend upon the protein expression levels. Diseaes 
such as Alzheimer’s, ulcer which occurs in brain and stomach respectively, the 
gene expression levels would also vary . In order to predict the disease based 
metabolic pathways we used four-layered network consisting of diseases, tissue 
based protein expression data, protein complex information and protein 
pathways network. The method can predict the biological pathways, the 
proteins which are involved and it can help to prioritize complex disease 
based pathways. 
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CHAPTER 2 
 
 
RANDOM WALK APPLIED TO DRUG TARGET BIPARTITE 
NETWORK 
2.1 INTRODUCTION 
 
Recent work has demonstrated the power of network-based approaches 
in drug discovery [33, 40, 41]. We have shown previously that a large 
semantic network of drug–target interactions provides a powerful framework 
for predicting new associations [42] and that an algorithm that predict drug-
target associations by using this network performs surprisingly well, even 
without training datasets or incorporating target preference [43]. zthis 
chapter, we apply a random walk-based link prediction algorithm based 
on Chen et al. [33] to a more extensive drug–target network from drug-
bank and evaluated its performance using an external bioactivity dataset 
from ChEMBL 15 database. We combine three networks drug-drug, target-
target, and drug-target to construct a heterogeneous network of drugs 
and targets. The links between drugs are obtained by quantifying molecular 
similarity with chemical fingerprints and examining the shared targets.  The 
links between targets are obtained by calculating local sequence similarity 
between proteins and again examining the links between shared drugs. 
2.2 METHODS 
 
We apply the RWR algorithm to a drug–target network and use an 
external dataset extracted from ChEMBL 15 (544 drugs and 467 proteins) 
at bioactivity cutoff points of 10µ M and 1 µ M to quantitatively evaluate 
the performance and robustness of the approach. 
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2.2.1   DATASETS 
 
For the drug dataset, I compiled a set of approved drugs from DrugBank 
database (Version 3.0) [44], consisting of 727 compounds and 3519 
protein targets. To construct the network between drugs, we incorporate 
two types of similarity measures: chemical (structural) similarity and 
target similarity. We calculate chemical similarity be- tween drugs by 
using the Jaccard Index (Tanimoto Coefficient) between their chemical 
fingerprints. The Jaccard Index is defined as the size of the intersection 
of two sets di- vided by the size of the union of the sets, ranging 
between 0 and 1. For binary vectors like chemical fingerprints, it is 
defined as C/(A + B-C) where C is the number of bits in common, A is 
the number of bits in one of the fingerprints, and B is the number of bits 
in the other fingerprint. We use four types of chemical features namely, 
MDL MACCS166 keys (fragmental descriptors) [45], ECFP6 fingerprints 
(extended connectivity fingerprint path 6) [46], 2D Pharmacophore 
fingerprints (PHFP4) [47] and ROCS program which uses Tanimoto combo 
similarity—which combines shape and color measures of a 
compound, we calculate them with ROCS program [48]. 
ECFP (extended connectivity fingerprint) encodes information on 
atom-centered fragments that is derived from the variant of the 
Morgan algorithm [49]. ECFPs are generated using the neighborhood 
of each non-hydrogen atom into multiple circular layers up to a 
given diameter. These atom-centric substructural features are then 
mapped into integer codes using a hashing procedure, which constitute 
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the extended-connectivity fingerprint. 
ECFP can, for instance, represent a very large number of features (over 4 
billion), do not rely on predefined dictionary of features, can represent 
stereochemical information, and can be interpreted as the presence of 
particular substructures. 2D pharmacophore fingerprints are calculated 
using topological (bond) distances. 
Pharmacophore fingerprints consist of pairs, triplets, or quartets of 
molecular features and the corresponding bond distances among them. 
We use PHFP 4 (quartets which includes number of bonds in the shortest 
path between the features) fingerprints for the calculation. The feature 
vectors of quartets involve four pharmacophoric features, six Euclidean 
distances separating those features, and an indication of chirality. For 
3D alignment and similarity we used ROCS 3.2, which is a shape-
similarity method based on the Tanimoto-like overlap of volumes. The 
alignment was developed using the Combo score, which combines the 
Tanimoto shape score with the color score that added the score for the 
appropriate overlap of groups with similar properties (donor, acceptor, 
hydrophobe, cation, anion, and ring) [http://docs.eyesopen.com 
/rocs/shapetheory.html] defined by SMARTS. Conformers for the data set 
is created using OMEGA [50], about 250 conformers with RMSD threshold 
of 0.6 is generated. ROCS performs shape-based overlay of conformers 
as atom-centered Gaussian functions. ROCS score performed in color 
optimization mode where it optimizes the molecular overlay to maximize 
both the shape overlap and the color overlap obtained by aligning 
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groups with the same properties that are contained in the color force field 
file. This overlay is then subsequently scored using the sum of shape 
Tanimoto for the overlay and the color score called Tanimoto combo 
score. We use Cs to refer the N-by-N chemical compounds similarity 
matrix. For the 727 drugs we used different chemical descriptors to 
calculate the Tanimoto similarity distribution to create a view of how 
similar the drugs look like. The distributions of different similarities 
Figure. 2.1 shows that for four finger- prints (166 MACCS Keys, PHFP4, 
3D ROCS, and ECFP6), 0.56% had a similarity above 0.7 for the MACCS 
keys, 0.31% had similarity above 0.4 for PHFP4, 0.88% had similarity 
above 1.2 Tanimoto Combo score for ROCS, 0.24% had similarity above 
0.3 for ECFP6. The mean similarity is 0.346, 0.019, 0.742, and 0.063 for 
MACCS, PHFP4, ROCS, ECFP6 fingerprints, respectively. This indicates 
how diverse chemical structures are in the drug dataset. 
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              Figure 2.1: Diagram showing distribution of chemical fingerprints.  
 
For the protein dataset, I extracted 3,519 target proteins across all 
available species and their sequences from the DrugBank database. As 
proteins in other species may provide useful information in our network-
based approach, we keep all the proteins regardless of species.  Note 
that, human proteins still dominate the dataset.  We calculate the 
sequence similarity matrix Ts  by using the R biostrings package and the 
normalization procedure proposed by Bleakley and Yamanishi [41]. 
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                                                ./ = &0 1,13&0 1,1 	 &0 13,13 ,																																												(2.1)	
 
where SW (·, ·) means the original Smith–Waterman similarity score. 
We constructed the drug-target relationship matrix A whose element A(i,j) 
is 1 if drug i interacts with target j, otherwise 0. The matrix is sparse; 
the total number of connections among the drugs and targets is only 
2,557, with 687 drugs having at least one known target and with 628 
proteins having at least one drug. There are 73 connected components in 
the whole drug target network dataset. The largest connected component 
in this bipartite graph has 498 drugs and 279 proteins. The connections 
are concentrated to a small number of drugs (see Fig. 2.2a) that affect 
nervous systems mostly psychoanaleptics and psycholeptics have the 
largest number of interactions. As most drugs are metabolized by 
cytochrome p450, which serves as an important protein target and enzyme 
for the drugs, the interaction between important enzymes CYP3A4, 
CYP2D6 and CYP3A5 are not considered on the drug target interaction 
matrix except for the drug paliperidone, which has interactions to all 
the three cytochromes targets mentioned above. 
Figure 2.2b exhibits the targets that interact with most number of drugs. 
The top frequent targets are Muscarinic receptor (ACM1), Adrenoreceptor 
alpha 1A (ADA1A), Histamine receptors (5HT2A), and dopamine receptors 
(DRD2). In addition to the drug–drug similarity matrix Cs (based on 
chemical similarity) and target–target similarity matrix Ts (based on  
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Figure 2.2: Diagram showing the distribution of compounds and   
                   targets in drugbank dataset. 
 
sequence similarity), we introduce additional measure of drug–drug and 
target–target similarities based on the network structure. 4/5  is a drug–
drug similarity matrix based on the number of shared targets between 
drugs; ./5is a target–target similarity ma- trix based on the shared drugs.  
The similarity between two drugs di  and dj  is quantified by Jaccard 
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coefficient, which is defined by: 
 
                                 4/5(78, 79) = ;<(8,9);< 8,8 =;< 9,9 >;<(8,9)	,																																																									 (2.2)					
where, Ml is the inner product of the drug-target interaction matrix. The 
similarity between targets is defined in the same manner. We define the final 
drug-drug similarity matrix Sd by taking a linear combination of the chemical 
similarity matrix (Cs) and target sharing similarity matrix (4/5). Similarly, the 
final target-target similarity matrix St is calculated using the sequence 
similarity matrix (Ts) and drug sharing similarity matrix (./5). 
2.2.2   RANDOM WALK WITH RESTART IMPLEMENTATION 	
We combined drug-drug, drug-target, and target-target networks into a 
undirected heterogeneous network. Many nodes have connections to both drugs 
and targets and we call them bridge nodes. At a bridge node, a random walker 
may jump to a node with the other type or to a node with the same type. The 
probability to do so is λ and 1-λ respectively. For instance, if a random walker is 
at a drug node, it can jump to one of the connected target nodes with the 
probability λ, or jump to connected drug nodes with the probability 1- λ. We call 
the parameter λ the jumping probability. If λ is 0, a random walker will explore 
only one type of networks. Most importantly, the probability p∞ (i) is the 
probability of finding the random walker at node i in the steady state. It gives a 
measure of probability of source and target node (proximity) between node 
i  and the source nodes where the random walks restarts. 
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The transition matrix is represented by,  
                              
W= !?? !?@!?@ !@@  
 
Here WTT is the target to target transition matrix, WDD is the drug to drug 
transition matrix, WDT is drug to target transition matrix and WTD is target to 
drug transition matrix. The calculation of each of the transition matrix in 
discussed in Chen et al [3]. The calculation of each of the transition matrix in 
discussed in Chen [33] given below in equation 2.3, 2.4, 2.5 and 2.6. The 
random walk is implemented on the heterogeneous network using the Eq. 2.7 
given below, 
The transition values of target vertexes from ti to tj is defined as 
   
																																				WTT(i,j)		=
&A 8,9/A 8,9B 																						CD	 E C, F = 09H>I &A 8,9/A 8,9 		B 																														JKℎMNOCPM																							(2.3)	
The transition values of drug vertexes from di to dj is defined as 
	
																																													WDD(i,j)		=
&Q 8,9/A 8,9B 																						CD	 E C, F = 09H>I &Q 8,9/Q 8,9 		B 																														JKℎMNOCPM																					(2.4)	
	
The transition values from target vertex ti to drug vertex dj is defined as 	
																																		WTD(i,j)		=	 IR 8,9R 8,9B 																						CD	 E C, F ≠ 090																																												JKℎMNOCPM																												(2.5)	
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The transition values from drug vertex di to target vertex tj is defined as 	
																																																WDT(i,j)		=	 IR 9,8R 9,8B 																						CD	 E F, C ≠ 090																																												JKℎMNOCPM																		(2.6)			
                                        pt+1 = (1 c)W T pt + cp0                                             (2.7)                                  	
pt  is a vector in which ith elements holds the probability of finding the random 
walker at node i at time step t. Initial probability vector p0 controls the restart 
probability c.  
																																																									p0  =  
(1 − ƞ)WXƞYX  (initial probability matrix )   
u0 and v0 be the initial probability vectors for target network and drug network, 
respectively. Parameter ƞ controls the importance of two kinds of seed nodes, 
i.e. drug node and target node. We tested the importance parameter ƞ  for 
different values ranging from 0 to 1.  
After a number of iteration steps, the pt converges to a steady-state probability 
vector p∞, where  p∞  =  
WZYZ .	In practice, we consider pt = p∞ if the change 
between pt and pt+1 (measure by the Frobenius norm) is less than 10-10.  
For finding novel targets for a given drug, we set the drug and the targets that 
are directly connected to the drug as our seed nodes. Suppose that there are six 
targets T1,…,T6 and four drugs D1, D2, D3, and D4. We focus on drug D3 and 
tries to find novel targets for D3. We already know that D3 interacts with T2 and 
T3. Then T1, T4, and T5  are candidate targets for drug D3. We set T2, T3,  and D3 
as the source nodes, namely 
                                      u0 = [0,1,1,0,0,0]T          and      v0=[0,0,1,0]T 
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The stationary probability p∞ represents the expected relevance of each 
drugs and targets regarding the source node set T2, T3 and D3. For instance, if 
the value for T1 is the largest among T1, T4 and T5, then we expect that T1 is 
most likely to interact with D3. 
 
2.3 RESULTS AND DISCUSSION 
 
2.3.1 EVALUATING PREDICTION PERFORMANCE USING LINK        
         PERTURBATION 	
The network-based method aims to predict new targets for a given drug. 
We evaluated our approach using a perturbed network where we have 
removed some links to measure how well our approach re-identifies those 
removed links. There are five parameter to explore: the restart probability 
c, the jumping probability λ, the relative importance η, which controls the 
relative importance between two types of seeds, wd  and wt  that weigh 
the drug and target similarity matrices and network based similarity 
measure of the drugs and proteins, respectively. Among these five 
parameters, we have tested η because, to our knowledge, the restart 
probability c, jumping probability λ and wd and wt are not likely to affect 
the results in a significant way. First, it is known that in most cases
the choice of restart probability c does not affect performance of 
PageRank algorithm and other PageRank based algorithms. For 
instance, the results of PageRank are highly insensitive to the choice of 
restart probability [28, 51] It has been shown that the prediction results 
from RWR are also robust [52, 53]. Because of these evidences, we 
	 27	
simply adopt the previously used value of 0.3 [33]. Second, the 
robustness of λ (jumping probability) has already been discussed [52–
54].  It has been shown that the weight parameters wd  and wt  are 
robust among the prediction results [33]. 
In our drug target network 684 (94%) drugs have at least one target. I 
prepare a test network of 684 drugs where I remove one links from 684 
drugs with a total of 684 drug–target interactions. The links include drugs 
which has only one target in order to see if the method able to predict 
single known interaction. We checked how many missing links are in top N 
of the ranked list. We divided the number of actual targets that are in 
the top N lists by the number of tests (684) and call the fraction as 
‘recovered fraction’. I also used a random set to calculate the statistics 
with same parameters and found that the results are way better than 
random set. I tested our results with different values of wd and wt  
ranging from 0 to 1 and found that at extreme point like 0 and 1 the 
performances drops radically but the performance gets best on values of 
wd and wt of 0.5 given in Additional file 3: Sheet 3 
(http://www.jcheminf.com/content/7/1/40#sec5). We tested different 
values of η for the four different chemical fingerprints to identify the optimal 
value of η and the right of chemical features. We observed that the 
prediction performance becomes optimal when η is small but not 0. I 
found optimal performance at η=0.01. For all the other values of η(0.1-0.9) 
the prediction rate for all fingerprints is equal. We found nearly 28% of 
the true interactions out of 684 can be retrieved at the top 10 rank 
positions and more than 38% of the interactions can be retrieved at the 
	 28	
top 50 rank positions. We also prepare 10 test networks of drugs that 
have more than two targets links, where we randomly remove 100–1,000 
links. Using the 10 test networks we predicted the removed links. We 
repeat this process, from preparing a test network to calculating the 
recovered fraction, 50 times to obtain the ‘average recovered fraction’. 
From Table 1 we can see that if we remove 100 links it gave us the best 
prediction rates and as we increase the number of removed links to 1,000 
the prediction rates falls. From Table 2 shows the recovered fraction rates 
for top 10, 25, 50, 100, 200, 500, 1,000 retrieved targets we also find 
almost 32% of the true interactions can be retrieved at the top 10 rank 
positions for each of the test networks and more than 75% of the true 
interactions can be retrieved at the top 50 rank positions. This 
indicates that the method performs well if I remove links from drugs 
which are having at least two or more known interactions, since it uses 
the given interaction information in the network. I also measured the 
area under accumulation curve, area under ROC curve AUC (Top 10%), 
BEDROC and enrichment factor given in Table 1. The area under the 
receiver operating characteristic (ROC) curve (AUC) is widely used to 
evaluate the performance of the ranking method. The advantage of 
using AUC is, the value ranges from 0 to 1 with 0.5 corresponding to 
randomness. Another key criterion for measuring the success of 
ranking prediction is the enrichment of annotated associations among 
top ranking associations. The higher the percentage of annotated 
associations among the top ranking associations, the better the 
performance of the prediction. The enrichment criterion is evaluated by 
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enrichment factor (EF) [52, 53]. EF reflects the capability of a screening 
application to detect true links (true positives) compared to random 
selection. Thus, its value should always be greater than 1 and the 
higher it is, the better the enrichment performance. When we are 
predicting links it should rank true links in the top-ranking list. Metric 
likes ROC not sensitive to early recognition for example considering cases 
like where (1) true links are retrieved at beginning of a rank ordered list, 
(2) where true links are randomly distributed and (3) where true links, 
which are retrieved in the middle of the rank, ordered list. In all of the 
above cases ROC is 0.5 but in terms of early recognition we see that case 
(1) is better than (2) and (3). To overcome these limitations methods such 
as RIE and BEDROC have been proposed. By changing the tuning 
parameter, α, one can test whether the method is able to rank true 
l inks  ea r l y  o r  no t .  
 
 
 
 
 
 
 
 
 
Table 2.1: Shows the statistical metrics with the number of links removed 
 
Number of links 
removed 
AUAC AUC BEDROC EF AUC(top 10%) 
100 0.947 0.991 0.833 9.23 0.867 
200 0.938 0.995 0.827 9.100 0.857 
300 0.930 0.995 0.818 8.95 0.845 
400 0.920 0.991 0.805 8.79 0.830 
500 0.916 0.997 0.801 8.71 0.824 
600 0.908 0.995 0.789 8.56 0.812 
700 0.899 0.981 0.780 8.42 0.802 
800 0.885 0.997 0.761 8.20 0.783 
900 0.869 0.955 0.741 7.91 0.765 
1000 0.854 0.956 0.715 7.62 0.741 
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We found that the performance of the algorithm for ranking the 
targets by different chemical features is approximately same which 
indicates using this approach a user can identify protein targets with 
any one set of chemical features. We used public 166 MACCS keys, 
ECFP6, PHFP4 and 3D ROCS to perform the analysis and it is 
surprising that the commercial programs feature performance is same 
as the 166 public MACCS keys. 
As a baseline, we test how RWR results differ from the results of 
random set of interactions. We randomized the interactions and 
similarity matrices and performed RWR and found the random set 
prediction rate was way below our original prediction rate as given in 
Additional file 3: Sheet 1. 
( http://www.jcheminf.com/content/7/1/40#sec5) 
 
# of links  
 
removed 
TOP 10 TOP25 TOP50 TOP100 TOP200 TOP500 TOP1000 
100 32.24 78.24 87.76 90.74 91.92 93.22 93.88 
200 31.92 77.95 87.26 89.86 91.15 92.37 93.12 
300 32.14 78.31 86.82 89.48 90.68 91.8 92.63 
400 32.04 77.4 85.34 88.07 89.24 90.33 91.45 
500 32.62 77.39 85.04 87.56 88.7 89.95 91.1 
600 32.53 76.21 83.68 86.23 87.54 88.86 90.16 
700 32.5 75.64 82.69 85.18 86.57 87.89 89.33 
800 33.06 74.13 80.88 83.45 84.86 86.35 87.97 
900 33.58 72.14 78.49 81.04 82.77 84.57 86.38 
1000 33.71 69.81 76.008 78.31 80.22 82.12 84.42 
 
Table 2.2: Shows the recovered fraction rates values with the number of links 
removed. 
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2.3.2 EVALUATING PREDICTION PERFORMANCE USING    
        EXTERNAL  DATASET FROM CHEMBL 	
In addition to the internal evaluation using link perturbation approach, 
we evaluate the performance of our method using an external dataset, 
namely ChEMBL version 15 database. From ChEMBL 15 data we extract 
all the drugs and targets that have activity values not more than 1 µM 
additional file 3 sheet (http://www.jcheminf.com/content/7/1/40#sec5) 
and and 10 µM additional file 3 sheet 4 (http://www.jcheminf.com/ 
content/7/1/40#sec5) with units IC50, Ki, Kd, EC50, AC50, LC50, and 
GI50. Our training model is based on DrugBank and UniProt database 
so we mapped the drugs and targets ChEMBL ids with the DrugBank ids 
and UniProt ids. We used pubchem mapping tool (http://pubchem. 
ncbi.nlm.nih,gov/idexchange)  to map ChEMBL ids to DrugBank ids 
and the UniProt mapping tool (http://www.uniprot.org/?tab=mapping) 
to map target ChEMBL ids to uniprot ids. It gives us 544 drugs and 
467 protein targets, with 3,463 and 564 drug target interactions those 
are below 10 and 1 µM, respectively. Naturally, there are lots of 
interactions that are present in both DrugBank and ChEMBL. We tested 
performance of parameter η at different values on ChEMBL 1 µM set and 
10 µM having which have more than 0, 1 and 2 target relations. Figures 
2.3 and 2.4 shows the recovered fractions against the rank with different 
η (eta) values for ChEMBL data at 1 and 10 µM cutoff with different 
fingerprints respectively. 
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Figure 2.3:  Showing the recovered fractions against the rank 
with different η (eta) values for ChEMBL datat at 1 µM cutoff. 
From Tables 2.3 and 2.4 we observe that RWR performance is better for 1 
µM target than 10 µM because at 10 µM we have lots off targets from 
different classes and as a result of that the prediction rate falls.  For 
ChEMBL 1 µM dataset, drugs having more than 0, 1 and 2 targets we 
achieve BEDROC score of 0.433, 0.553 and 0.611, respectively, which is 
much better than a random set of interactions.  To test whether random 
walk performs better than just a simple sequence similarity search we 
took the approved drugs and it’s known targets from the ChEMBL 10  
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Figure 2.4 Showing the recovered fractions against the rank with different η 
(eta)   
           values for ChEMBL datat at 10 µM cutoff. 
 
µM dataset and performed sequence similarity based such against 3,519 
targets and ranked them. We found RWR performance is way better in 
ranking targets than performing simple sequence based search. The 
results are shown on Tables 3 and 4. This is the first time that the 
random walk-based method is evaluated using a binding assay dataset. 
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Data types Number of targets AUAC AUC BEDROC EF AUC(Top  
10%) 
ChEMBL 1 uM (RWR) 
ChEMBL 1 uM (Seq) 
ChEMBL 1 uM (random RWR) 
ChEMBL 10 uM (RWR) 
ChEMBL 10 uM (Seq) 
ChEMBL 10 uM (random RWR) 
ChEMBL 1 uM (RWR) 
ChEMBL 1 uM (Seq) 
ChEMBL 1 uM (random RWR) 
ChEMBL 10 uM(RWR) 
ChEMBL 10 uM (Seq) 
ChEMBL 10 uM (random RWR) 
ChEMBL 1 uM(RWR)  
ChEMBL 1 uM (Seq) 
ChEMBL 1 uM 
ChEMBL 10 uM(RWR) 
ChEMBL 10 uM (Seq) 
ChEMBL 10 uM (random RWR) 
> 0 
> 0 
> 0 
> 0 
> 0 
> 0 
> 1 
> 1 
> 1 
> 1 
> 1 
> 1 
> 2 
> 2 
> 2 
> 2 
> 2 
> 2 
0.709 
0.67 
0.494 
0.596 
0.518 
0.394 
0.784 
0.652 
0.483 
0.613 
0.551 
0.514 
0.823 
0.701 
0.533 
0.632 
0.569 
0.521 
0.995 
0.67 
0.493 
0.837 
0.518 
0.364 
0.784 
0.651 
0.483 
0.61 
0.552 
0.514 
0.824 
0.705 
0.533 
0.633 
0.569 
0.521 
0.433 
0.396 
0.075 
0.323 
0.237 
0.036 
0.553 
0.39 
0.081 
0.353 
0.279 
0.075 
0.611 
0.513 
0.0671 
0.399 
0.298 
0.262 
5.058 
4.48 
1.09 
3.865 
2.641 
0.954 
6.286 
4.507 
1.29 
4.091 
3.084 
1.244 
6.866 
5.109 
1.465 
4.569 
3.03 
1.95 
0.455 
0.414 
0.079 
0.351 
0.2555 
0.029 
0.569 
0.412 
0.083 
0.378 
0.3 
0.088 
0.631 
0.469 
0.065 
0.422 
0.315 
0.125 
 
Table 2.3: Shows the types of data we used the drug target 
interaction having more than 1 and 2 drug interactions. 
2.4  CASE STUDY: PROFILING TOP SELLING DRUGS 
 
  Here, as a case study we investigate the target profiles of the popular 
top selling drugs in 2012 [54]. First, we consider u∞, the steady-state 
probability vector for the targets in our framework, as ‘target profile’ of 
a drug.  Then we examine the top 10 predicted targets for the top 
selling drugs. We find that some targets are associated with many drugs 
(see Table 2.5). For instance, adrenoceptor alpha 1A appears in 60% of 
drug’s top 10 target association lists; serotonin receptor 5HT2A appear 
in 43%; and adrenoceptor alpha 1B in 35%. Most drugs shown on the 
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Table 2.5 mostly belong to the rhodopsin class of GPCR’s. In Additional 
file 4, (http://www.jcheminf.com/content/7/1/40#sec5) predictions 
are provided for 110 drugs with 3,519 targets and Fig. 2.5 shows a 
bipartite network of 110 drugs with top 10 predicted targets for each drug. 
We took some random drugs and tried to find known binding 
associations to protein targets. We searched three databases ChEMBL 
[55], PDSP [56], and Pubchem [57] using the binding coefficients like 
IC50 and Ki. Table 2.6 lists the 10 predicted drug–target associations 
that we have identified evidence of binding interaction in other databases. 
These findings suggest that these targets may have many undiscovered 
interactions with existing drugs. Further investigation may have 
significant values on understanding side effects of existing drugs as well 
as repurposing them. 
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Data types Number of targets Top 10 Top 25 Top 50 Top 100 Top 200 
ChEMBL 1 uM (RWR) 
ChEMBL 1 uM (Seq) 
ChEMBL1uM(random RWR) 
ChEMBL 10 uM (RWR) 
ChEMBL 10 uM (Seq) 
ChEMBL 10 M (random RWR) 
ChEMBL 1 uM (RWR) 
ChEMBL 1 uM (seq) 
ChEMBL 1 uM ((random RWR) 
ChEMBL10uM (RWR) 
ChEMBL 10 uM (seq) 
ChEMBL 10 uM (Random RWR) 
ChEMBL 1 uM (RWR) 
ChEMBL 1 uM (seq) 
ChEMBL 1 uM 
ChEMBL 10 uM (RWR) 
ChEMBL 10 uM (seq ) 
ChEMBL 10 uM ((Random RWR) 
> 0 
> 0 
> 0 
> 0 
> 0 
> 0 
> 1 
> 1 
> 1 
> 1 
> 1 
> 1 
> 2 
> 2 
> 2 
> 2 
> 2 
> 2 
0.144 
0.164 
0.002 
0.11 
0.122 
0.014 
0.274 
0.189 
0.007 
0.22 
0.13 
0.014 
0.271 
0.19 
0.006 
0.233 
0.13 
0.012 
0.342 
0.315 
0.013 
0.247 
0.183 
0.023 
0.477 
0.35 
0.023 
0.277 
0.212 
0.023 
0.518 
0.393 
0.018 
0.297 
0.22 
0.028 
0.47 
0.394 
0.018 
0.324 
0.234 
0.035 
0.55 
0.428 
0.038 
0.348 
0.276 
0.035 
0.598 
0.53 
0.034 
0.353 
0.295 
0.04 
0.532 
0.42 
0.036 
0.386 
0.249 
0.048 
0.58 
0.472 
0.076 
0.417 
0.296 
0.048 
0.634 
0.56 
0.055 
0.4299 
0.316 
0.057 
0.607 
0.43 
0.021 
0.409 
0.254 
0.079 
0.614 
0.513 
0.091 
0.446 
0.302 
0.079 
0.677 
0.598 
0.08 
0.472 
0.324 
0.093 
 
Table 2.4: Table shows the hit rate for drugs having more than 1 and 2   
                 drug Interactions 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 Table 2.5: Table shows the hit rate for drugs having more than 1  and  
            2 drug interactions well as repurposing them. 
Targets 
% of drugs associated 
with the targets 
% of drug associations 
appearing in prediction. 
ADA1A 7.27% 60% 
5HT2A 4.54 43.63% 
ADA1B 7.27% 35.45% 
5HT1A 4.54% 33.63% 
ADRB1 5.45% 31.81% 
5HT1B 5.45% 30.90% 
5HT2C 3.63% 30% 
ACM2 9.09% 26.36% 
5HT3A 4.54% 25.45% 
5HT1D 5.45% 23.63% 
ACM3 9.09% 21.81% 
5HT7R 4.54% 18.18% 
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Finally, let us summarize the contributions of this paper. First, we offer 
a general approach that takes the whole drug target network into 
account without separating protein categories, in contrast to the 
previous study [33]. The following estimation corroborates our 
approach. Our drug-target dataset contains 727 drugs and 3,519 
proteins. The number of interactions between drugs and targets is 
2,557, which makes 684 drugs to have at least one known target and 
457 drugs to have two or more interactions. The proteins in the dataset 
are grouped under 15 different categories according to ChEMBL target 
classifications (https://www.ebi.ac.uk/chembl /target/browser). Out of 
3,519 proteins, 1,386 proteins belong to one of the categories and 
other proteins do not have category information. The number of drugs 
that have at least two interactions with proteins that are categorized is 
412. Among these 412 drugs, the number of drugs that have 
interactions with proteins from multiple groups is 169. In other words, 
we estimate that about 40% of drugs have interactions across multiple 
groups according ChEMBL dataset. Therefore, it is more reasonable to 
consider all proteins together, rather than running the prediction model 
separately for each category. 
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Figure 2.5: Shows the network of the top 10 predicted targets of 110 
drugs 
 
Protein Drug Source Activity Tpe Activity  M 
5HT2A Carvedilol Pubchem AID 625192 IC50 0.41 
5HT2A Desloratadine Pubchem AID 625192 IC50 0.033 
KCNH2 Lidocaine ChEMBL IC50 263.02 
ADRB1 Salmetorol ChEMBL IC50 0.501 
5HT1A Amphetamine PDSP database Ki 6.6 
HDAC2 Atorvastatin ChEMBL IC50 22.5 
ADA1A Duloxentine PDSP Ki 10 
ACM1 Montelukast Pubchem AID 625153 IC50 8.045 
SC6A4 Quetiapine PDSP Ki 10 
 
Table 2.6: Drug target interactions with association values from different     
             Databases 
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Second, we further investigate the methodology by presenting a benchmark 
of a parameter η in conjunction with the four chemical fingerprint types: 
MACCS 166 keys, ECFP6 fingerprints, PHFP4 fingerprints, and ROCS. In 
the previous study, the parameter space of η is not explored below 0.1, 
but we find that we can improve the performance by de- creasing η 
below 0.1. We also find that the performance is robust under the choice 
of chemical fingerprinting method, particularly when η is around the 
optimum (0.01). Very small η means the walk in the target network is 
much more important than the walk on the drug–drug network. In a 
sense, it indicates that drug network add some information but only 
marginally. And also the drug network is not very useful in prioritizing 
targets. 
2.5 CONCLUSION 
 
We have demonstrated that RWR approach provides a powerful way of 
predicting of drug–target interactions. There are two significant benefits 
of the approach. First, it provides a natural way to integrate multiple 
types of information such as drug–drug similarity, target–target 
similarity, and existing drug–target interactions into a coherent 
framework.  Second, in contrast to other approaches like short-path-
based methods, the random walk framework incorporates the network 
structure around a single or multiple points of interests extensively, 
taking into account not only the closeness of targets, but also the 
multitude of the paths to the targets. These properties allow us to 
predict novel targets even for the drugs that have no known target, by 
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connecting such drugs to the network through the drug–drug similarity. 
Still, the performance of RWR could be further improved by incorporating 
more known drug–target interactions. We have studied the performance 
of the method under the variations of η parameter and the choice of 
fingerprints methods, showing that while training the model one can use 
any of the chemical features as similarity matrix with parameter η=0.01 
to obtain the predicted results, without significantly affecting the 
outcomes. 
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CHAPTER 3 
 
 
SYSTEMIC IDENTIFICATION OF DISEASE ASSOCIATED 
PATHWAYS BY RANDOM WALK WITH RESTART 
 
3.1 INTRODUCTION 	
One of the fundamental challenges in human health in elucidating the 
molecular basis of hereditary diseases. Pioneering studies by Goh [58, 
59] have resulted in the definition of Human Disease Network (HDN) 
which helped relate these diseases through shared genes, shared 
proteins, regulatory proteins, shared pathways and similar gene 
expression profile. Recent advances in genomics, molecular and cell 
biology, biochemistry have allowed us to visualize the organization of 
disease complexity at multiple scales involving - molecular data, proteins, 
tissues, pathways and organ level data. Understanding the relationships 
between different scales of organization will allows us to study drug 
interactions and its effects at molecular levels and organismal effects [60]. 
The biological function or the pharmacological effect can be studied based 
on an organ tissue based system where proteins are interacting with 
each other by non covalent interactions and forming complexes which 
takes part in biological pathways. If genetic variants occur in these 
protein complexes it can alter the function of entire complex and may 
alter the normal pathway to cause a disease. A pathway consists of 
series of related reactions, whereby the reactions are linked through 
common compounds (metabolic pathways) or through the common 
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macromolecular complexes (protein-protein interaction pathways). To 
understand the molecular basis of disease it is important to understand 
the biological pathways and how the proteins are coordinating among 
themselves in a network of protein-protein interactions. However, the 
interactions are condition and tissue specific i.e. for a particular tissue 
and disease some proteins are differentially expressed and have varied 
interactions among the proteins to activate various pathways [61]. 
It is common for the diseases to get associated with a specific tissue 
types. For example for metabolism of drugs, genes like Cytochrome 
P450 would differentially express in liver than in brain, thyroid, tonsil 
or skin. Similarly, genes for Parkinson’s disease would differentially 
expressed in brain rather than in liver or rectum. The idea here is to 
find associations of tissue specific disease pathways. This would 
empower us to select pathways where the disease genes are cooperating 
among themselves. Biological pathways represent biological reactions 
and its interaction network within a cell. Each reaction is identified by 
an enzyme, which is coded by a gene. Various Gene prioritization 
algorithms use protein interaction networks, ontologies, gene expression 
data to prioritize candidate genes for diseases [28, 62, 63]. However 
using only protein-protein interaction data or gene expression data it is 
not possible to detect the molecular basis of the disease and how 
symptoms are raised. It is very important to map expression of genes 
to the tissues and the tissues to diseases [64]. But to understand the 
molecular basis of disease we should emphasize in understanding the 
biological pathways and how the proteins are coordinating among 
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themselves inside a specific tissue. 
In the past methods were developed to map protein complexes to specific 
diseases and then use such information to facilitate prediction of disease 
genes. For example, Lage etal. [65] Identified aggregates of proteins 
connected to candidate protein in a PPI network as a protein complex 
infer association between the candidate protein and a query disease 
based on members of the protein complexes [66]. Vanunu etal. [67] 
proposed a random walk method where the edge weights are normalized 
by degree of the targets to prioritize protein complexes associated with the 
disease. Magger etal. [30] used 60 different tissue specific networks for 
finding disease related genes and found high precision in finding disease 
related genes. Tissue-specific networks can reflect the related diseases 
better than using normal global ppi networks. Most of them worked with 
disease – disease network, ppi network and a bipartite disease – protein 
network. None of them extended their algorithms beyond 2 layers of 
networks. This work attempts to extend the network layers to four layers 
namely disease, proteins, protein complexes and biological pathways. 
In this chapter we propose an approach for identification of biological 
pathways that are related to a query disease via a random walk model on 
a large heterogeneous network that is composed of disease-disease 
similarity layer, a tissue based protein-protein interaction layer, a protein 
complex layer and finally complex and pathway membership layer. 
Association between protein complexes and pathways are made based 
on interdependency measure between complex-proteins and protein-
pathways, and is described in detail in methods section. Starting from 
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the query at the disease layer the random walker travels in a four 
layered network and scores a biological pathway using the probability 
that the walker stays in the pathway layer at steady state and ranks 
the pathways according to the probability scores. We validate our 
method by cross validation technique in which from a query disease we 
removed all the associated proteins and tried to predict whether the 
given disease-pathway relation can be predicted using our method. 
 
 
Figure 3.1: Diagram showing the workflow of disease to pathway  
                  prediction. 
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3.2 METHODS 
 
3.2.1 DATASETS AND PRE-PROCESSING 
 
In this chapter we are dealing with four different types datasets namely 
diseases, protein- protein interactions, protein complexes and pathway 
information. We describe below how we use them in our model 
generation. For our work, we used 926 diseases and 60 tissue 
associations (DisT), which is provided by Jacquemin etal. [68] . Van Driel 
etal [69] used MeSH vocabulary to create a weighted vector composed of 
phenotype terms and quantified the similarity between the diseases based 
on the cosine similarity scores for 5080 diseases. We got the tissue specific 
PPI network data from Magger etal [30]. The PPI data consist of 9998 
proteins with 41,049 interactions. Magger used two types of networks one 
generated using the edge reweighted strategy and other node removal 
strategy [70]. In this chapter we used edge reweighted PPI network rather 
than the node removed network, because node removed network is a very 
strict method of eliminating unexpressed proteins, in which nodes
are removed from the network if the proteins are not expressed in 
the relevant tissue. This changes the topological property of the 
network consisting of multiple components. Edge reweight method 
assigns a continuous value for the interaction based on the 
expression of the two interacting proteins. It uses a penalty factor, 
which is multiplied to the original PPI network such that when it 
is 0 then we have node-removed network and when it is 1 we have 
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the full original PPI network. Magger used a network with penalty factor 
0.1 which achieved maximum precision in identifying disease genes and 
retaining its full network topology. Since the Node removed network is 
likely to be less robust to noisy data such as gene expression and hence 
we selected the edge reweighted PPI network in the current study. In 
order to see, weather using tissue based PPI network increases precision of 
disease pathways associations we created a non-tissue based PPI network 
by calculating the average of the edge weights of 60 different tissue based 
PPI networks. We extracted disease-protein associations using Biomart tool 
[71], obtaining a total of 6,015 associations between 4,085 diseases and 
3,418 proteins. We mapped the disease and proteins ids to the OMIM and 
PPI network proteins, which resulted in 1,670 diseases, and 1,338 proteins 
with 2,091 associations in all. We used protein complex information from 
the CORUM database [72] accessed (January 4th 2015) and extracted 
1826 human protein complexes, which has complex names and one of 
proteins in the complex can be mapped to PPI network of proteins.  We 
made a protein complex matrix containing 8268 binary associations. For 
the complex pathway relationship we downloaded all the pathways 
information from ConsensusPathDB database [73]. This database not only 
integrates information from KEGG [74] but also from several other 
resources like PharmGKB [75], SMPDB [76], Reactome [77], Wikipathways 
[78], HumanCyc [79], Biocarta [80], Netpath [81], and EHMN [82]. I had 
2145 proteins ids linked with 2531 pathways with 45,669 associations. 
For Complex pathway association we used an interdependency measure 
between the protein–complex and protein–pathways and associations 
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between them that are significantly interdependent were identified and 
kept in the complex pathway association contingency table. To compute 
the pathway and protein complex associations we first create a 
contingency table, which is shown in table 3.1 of M rows and N columns. 
In the table, Oij denotes the number of occurrences of proteins that are 
shared by complexes and pathways. 
 	 	 pathway1 pathway2 pathway3 .... pathwayj 
P complex1 O11 O12 O13 ... O1j 
P complex2 O21 O22 O23 ... O2j 
P complex3 O31 O32 O33 ... O31 
P complex4 O41 O42 O43 ... O4j 
P complexi Oi1 Oi2 Oi3 ... Oij 
     
   Table 3.1: Protein Complexes and Pathway occurrence matrix   
 
Let ,  M\]89 = ^_`	^`B?   be the expected number of occurrence’s of Oij ,where 
Oi+ = abcdH ik  and  O+j = a;cdH kj and T = ae,c lk  . An interdependency 
relationship is considered to exist if Oij is significantly different from expij. 
To calculate the significance we calculate an adjusted residual test 
statistic as discussed in Jong et al. [83] given below, 																																																																							f789 = 	 g_B(H>h_i` ) (H>h`Bi )																																										(3.1)	
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where,  																																																																						j89	 = ^_B>	k-l_Bk-l_B 																																																												(3.2)	
 and (1 − ^_?` ) (1 − ^`B? )  is the maximal likelihood of Zij .  
adij has an approximate normal distribution of with mean zero and 
variance of approximately one. So if the absolute value exceeds 1.96 then 
it would be considered significant at alpha = 0.05. Based on equation 
(3.1) we can compute the interdependency relationship between complex 
and pathways and prepare a adjusted contingency table. There
we convert all the absolute values < 1.96 to 0 in the current adjusted 
contingency tables and create the final complex-pathway association 
matrix. 
 
3.2.2     OVERVIEW OF THE RWR METHOD  		
We modeled pathways associated with the diseases as a random walk 
based prioritization method [84–87], in which given a query disease and a 
set of predefined pathways as seeds, we first identify the tissue to which 
the disease is most likely related and then get the associated network 
for that tissue. Once this step is done then we construct a tissue–specific 
disease-protein-complex–pathway network, which is a heterogeneous 
network composed of 4 layers. Then I apply the random walk with restart 
algorithm to this network to calculate the score for each pathway and 
rank the candidate pathways. The network I constructed consist of four 
different layers the top layer consisting of disease similarity (DDij )lxl , 
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where l is number of diseases We used two different methods to create 
similarity network first, with a K-nearest neighbor (KNN) strategy where 
we use 15, 20, 25, 30 nearest neighbors to build 4 different types KNN 
disease networks. Second, with a threshold cutoff of 0.3, 0.4, and 0.5 on 
the disease similarity network we build three types of threshold 
networks. In both the strategy we further consider two variations to keep 
the weights as unweighted. In both the cases we choose normalize the 
edge weights by degree of the nodes. For that we define a diagonal matrix 
L such that L(i, i) is a sum of row of i of similarity matrix S we set S’ = L-
1/2 S L-1/2 which gives us a symmetric matrix S’ij = 
&_B@ 8,8 @(9,9) .  S’ij is also known 
as the normalized laplacian. 
We connect the disease layer to the protein-protein network layer (PPij)mxm using 
the disease–protein association matrix (DPij.)lxm where, m is total number of 
proteins. For each of the query disease we load the corresponding PPI network 
and normalize it by node degree.   
The next we connect the proteins from the PPI network to the protein 
complexes by using undirected edges to form a matrix (PCij)mxc where , c is the 
total number of complexes. We didn’t connect complexes between themselves 
and we normalize the adjacency matrix between complexes and proteins from 
the PPI network based on its degree of the nodes.  
The last and the bottom layer we connect the complexes to the pathways using 
weighted and unweighted edges to form a matrix (CPaij)cxp where , p is the total 
number of proteins. Also we left the pathways unconnected in the study. . If we 
put all the matrices together we get a large transition matrix W of 19435 x 
19435 elements given below as , 
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m = nn no n4 nofno? oo o4 oofn4? o4? 44 4ofnof? oof? 4of? ofof  
 
This matrix can be written as , 
m = nn no 0 0no? oo o4 00 o4? 0 4of0 0 4of? 0  
 
In the transition matrix W, 0 stands for a zero matrix indicating no transition 
between the nodes and superscript T stands for the transposition of the matrix. 
We used two types of normalization for the full network, 
 One is the column normalized where the edges are normalized by    
   column sums, 
 Laplacian based where the edge weights are normalized by source   
   and target degrees, 
We used two types of datasets, 
  60 Tissue based PPI networks, 
•  global PPI network where we use the average of the confidence  
           scores of 60 different tissues and create a global network to    
        predict the associations. 
In total I used three type of datasets in order to check performance of 
the method and parameters, 
 Laplace normalized Tissue non-specific network 
 Laplace normalized Tissue based PPI network 
 Column normalized Tissue based Network. 
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3.2.2 RANDOM WALK PROCESS: 
The user gives the source disease and target pathway as the seed nodes. 
We initialize a query vector of seed nodes (Po)l+m+c+p which represents 
the prior probabilities when a random walker starts its journey. In this 
vector all the seed nodes are initialized to 1 and the remaining ones to 0, 
we then normalize the query vector. 
p0		=		 (1 − $)&'00$)' 	
u0 and v0 be the initial probability vectors for disease network and 
pathway network and we initialize the protein and complex vectors as 0. 
Parameter γ controls the importance of two kinds of seed nodes, i.e. 
disease node and pathways node. We tested the importance parameter γ 
for different values ranging from 0.5, 0.7 and 0.9.  We use (Pt)l+m+c+p  to 
represent the probabilities that the random walker stays on the nodes at 
time steps t.  After a number of iteration steps, the Pt converges to a 
steady-state probability vector P∞, where we represent the probability P∞ , 
the probability of finding the random walker in the steady state, which 
can be determined by change between Pt  and Pt + 1 (L1 norm) is less 
than 10−7 a random walker chooses the query of interest and at each 
time step of the walking process the walker may start a new journey with 
probability c or may move to its neighbor’s with probability 1 − c according 
the transition value matrix W . The random walk is implemented on the 
heterogeneous network using the equation given below, 
                                     Pt+1 = (1 − c)WT Pt + cP0                             (4.3) 
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After the steady state is achieved we normalize the scores and further rank 
the candidates in a decreasing order of the probability scores. As a 
baseline we also made randomized networks for each of the type of 
parameters and tested the performance as well as the significance. 
3.3 RESULTS AND DISCUSSION 
 
3.3.1 EVALUATING PREDICTION PERFORMANCE USING   
        LINK PERTURBATION: 
The network based method aims to predict new pathways for a given 
disease. To evaluate our method we created a test set consisting of 
associated diseases, tissues, proteins and pathways and a set of control 
objects as those that neither link to the disease and protein in the 
training data not in the test data.  Then we perturbed the network were we 
remove all the links between a disease and its associated proteins and 
calculate discriminant scores for both the test and the control objects, 
and we rank each test object against all control objects in non-ascending 
order according to their proximity scores.  Repeating the above ranking 
procedure for all test cases, we obtain a set of ranking lists and further 
calculate some accuracy measure like auc, auc top 10%, bedroc [53] and 
enrichment factor. 
The area under the receiver operating characteristic curve (AUC) is widely 
used to evaluate the performance of the ranking method. The advantage 
is, the value ranges from 0 to 1 with 0.5 corresponding to randomness.   
AUC has been criticized as an inappropriate method and is not sensitive to  
early recognition [52,88,89].
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A key criterion for measuring the success of ranking prediction is the 
enrichment of annotated associations among top ranking associations. The 
higher the percentage of annotated associations among the top ranking 
associations, the better the performance of the prediction. The enrichment 
criterion is evaluated by a numerical factor (EF) defined as, 
                             EFset   =  (Ha/Ht)/(A/D)                              (3.4) 
where , Ht total number of links retrieved, Ha is the total number of true 
links retrieved in the links list. A represents the total number of true links 
in the database and D stands for total number of interactions both positive 
and negative links. The enrichment factor reflects the capability of a 
screening application to detect true links (true positives) compared to 
random selection. Thus, its value should always be greater than 1 and 
the higher it is, the better the enrichment performance of the virtual 
screening. The EF overcomes this problem but it is dependent on the ratio 
of true links to non-links and the choice of X (ratio of the top ranked 
links). Similarly when we are predicting links it should rank true links in 
the top-ranking list. Metric likes ROC not sensitive to early recognition 
for example considering cases like where, 
 
 true links are retrieved at beginning of a rank ordered list, 
 where true links are randomly distributed 
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 where true links, which are retrieved in the middle of the rank, 
ordered list 
 
In all of the above cases ROC is 0.5 but in terms of early recognition we 
see that case (1) is better than (2) and (3). To overcome these limitations 
methods such as RIE [88] and BEDROC [52] have been proposed. By 
changing the tuning parameter,α, one can test whether the method is able 
to rank true links early or not.  In order to check performance we used 
two metric known as the relative rank and precision. For calculation of 
relative rank, we calculate the relative rank of all the predicted links for a 
particular disease by taking the ranks and dividing it by N (total number of 
true links) and then we calculate the average of the ranks for all the 
predicted pathway links for a queried disease. For precision criterion, we 
calculated the precision within the cutoff of top rank 100. In our test set 
a disease is associated with more than one pathway and proteins, for a 
particular disease we randomly select one of the pathway as the seed node. 
For a queried disease we remove all the disease – proteins links from the 
DP matrix, recalculate the transition value matrix in order to predict 
other associated pathways for the queried disease. As we remove all of the 
disease proteins links from the queried disease now the random walker 
will depend on nearest associated diseases and its associated proteins to 
make the walk and predict the pathways. We tested the parameters γ 
with different KNN and thresholds on the disease similarity network. We 
performed leave-one-out cross-validation experiment using this network.
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3.3.2  COMPARISON OF DIFFERENT STRATEGY FOR CONSTRUCTING   
          THE NETWORK 
We considered two different strategies for creating the disease similarity 
network as the top layer of the disease-protein-complex-pathway network: 
one K nearest neighbor (KNN) and other is δ-threshold strategy. Also we 
considered two strategy to construct the protein- protein interaction 
network: one used edge reweighted network which consists of network 
from sixty different tissues and the other one we took the average of all the 
networks from all tissue related network and considered a tissue non-
specific for prediction. We also checked the performance of the methods 
with different parameters and with different normalizations with a random 
network as a baseline. Table 1 and Table 2 represent the results of the 
KNN strategy and δ-threshold strategy respectively.   We didn’t present 
the full set of results. 
 
Table 3.2: Results of the K-nearest neighbor (KNN) based disease network 
using the parameters on table 3.2 and table 3.3 however, we shown the 
γ Relative  
Rank 
rrankRa
nk 
Precisio
n 
AUC AUCTO
P (10%) 
BEDROC EF Data Normalization KNN 
0.5 153.074 0.495 0.738 0.205 0.228 3.262 LaplaceNormalized tissue non-specific 20 
0.5 157.564 0.499 0.733 0.202 0.223 3.267 Laplace Normalized Tissue Based  25 
0.5 213.128 0.364 0.669 0.167 0.183 2.581 Normalized Tissue based 20 
0.7 152.027 0.513 0.742 0.21 0.23 3.333 Laplace Normalized tissue non-specific 25 
0.7 158.268 0.478 0.732 0.2 0.222 3.227 Laplace Normalized Tissue Based  30 
0.7 158.268 0.38 0.679 0.158 0.162 2.591 Normalized Tissue based  15 
0.9 156.937 0.498 0.737 0.202 0.224 3.328 Laplace Normalized tissue non-specific 20 
0.9 155.982 0.496 0.735 0.202 0.222 3.265 Laplace Normalized Tissue Based 30 
0.9 210.23 0.36 0.675 0.158 0.177 2.535 Normalized Tissue based 15 
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KNN results and δ-threshold using different γ parameter values with best 
KNN value from different tissue based PPI networks and two types of 
normalizations. 
We observe that our method is quite robust to the number of 
neighboring diseases in the KNN-strategy and well as the γ-threshold 
strategy for both the Laplace normalized tissue specific network and as 
well as the Laplace normalized tissue non-specific network. For KNN-
strategy we have achieved a mean relative rank, AUC, AUCTOP, 
BEDROC, EF of 152.027, 0.742, 0.210, 0.230, 3.33 with Laplace 
normalization, using a tissue non- specific PPI network, KNN of 25 and γ 
of 0.7. We also found close scores for Laplace normalized tissue based 
PPI network with Relative Rank, AUC, AUCTOP, BEDROC, EF of 157.564, 
0.733, 0.202, 0.223, 3.267 with KNN of 25 and γ of 0.5. We observe that 
for a column normalized tissue based PPI the  Relative  Rank,  AUC,  
AUCTOP,  BEDROC, EF is well below the laplacian Normalized ones which 
illustrate that Laplacian normalized increases the prediction performance. 
We noticed that for δ-threshold strategy we get a better performing 
model than the KNN-strategy.  For δ-threshold of 0.3, we have achieved a 
mean relative rank, Precision, AUC, AUCTOP, BEDROC, EF of 149.012, 
0.521, 0.747, 0.220, 0.240, 3.494 using Laplacian normalized tissue based 
PPI network with γ of 0.9. The results obtained are almost same as γ of 0.9 
and δ-threshold of 0.3. Around these parameters the δ-threshold strategy 
holds the higher performance than KNN-strategy. Therefore we 
recommend to use δ-threshold strategy in disease similarity network 
along with laplacian normalization of matrices and for PPI we found 
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Tissue based PPI networks performance is higher than tissue non-specific 
one. 
Figure 3.2 shows the precision plots for both the threshold and KNN 
strategy compared against each other with different types of datasets 
along with a randomized dataset. For KNN at different γ parameter 
values, we found that at KNN = 25 and γ = 0.7 it achieves a precision of 
0.517 for top 100 rank pathways. In threshold strategy at different γ 
parameter values, we found that at threshold = 0.3 and γ = 0.9 it 
achieves a precision of 0.555 for top 100 rank pathways which confirms 
us that threshold strategy is suitable for our dataset. 
Also as a baseline we also make randomized networks and made 
predictions and checked the performance for KNN strategy and δ-
threshold at γ parameter values. The ROC plots are shown for both KNN 
and δ-threshold on figure 3.3 illustrate better predictive performance of 
laplacian normalized tissue based network against random network. 
The restart probability c determines the possibility of jumping from any 
node in the network back to the starting point of the query disease. With 
a large value of c, a random walker cannot go far away from the starting 
point and thus will mainly explore neighboring nodes of this point, while 
with a small value of c, the random walker is able to explore areas far away 
from the starting query disease. We computed Relative Rank, AUC, 
AUCTOP, BEDROC and Enrichment Factor for laplacian normalized tissue 
based PPI network with different Restarts from 0.1 – 0.9 as shown on table 
3.4 we observe that our method shows small variations, however at restart 
of c=0.9, we have best AUC of 0.747, AUC TOP (10%) of 0.22, BEDROC 
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(α=20) of 0.24 and enrichment factor (EF) of 3.493. From these observations 
we conclude that the selection of parameter c = 0.9 results in improved 
performance of our approach as shown in table 3.3 . 
 
Restart (c) Relative Rank AUC AUCTOP BEDROC Enrichment 
0.1 152.9424 0.721 0.184 0.193 3.173998 
0.2 155.0584 0.718 0.185 0.191 3.143087 
0.3 165.5083 0.7 0.159 0.167 2.88128 
0.4 166.8327 0.697 0.164 0.171 2.729648 
0.5 171.7294 0.689 0.162 0.167 2.674881 
0.6 159.7915 0.712 0.177 0.191 3.025033 
0.7 149.3544 0.74 0.205 0.226 3.244651 
0.8 149.0128 0.745 0.213 0.236 3.407035 
0.9 148.4792 0.747 0.22 0.24 3.494314 
 
Table 3.3: Results of Laplacian Normalized Tissue based PPI with different 
restarts values 
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Figure 3.2: Showing precision plots for different γ’s with KNN   
               strategy  and threshold 
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Figure 3.3: Showing ROC plots for different γ’s with KNN strategy   
                and threshold strategy. 	
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3.4    CONCLUSION 
 
In this chapter we have proposed a method for identification Biological 
pathways related to a query disease via random walking on a 
heterogeneous network that is composed of four different layers the 
disease layer, protein layer, protein complex layer and the protein 
pathway layer. We have shown a good performance of our method via 
large-scale leave out cross validation approach and optimized the 
parameters c, γ for better results. We tested two different types of disease 
similarity network types like KNN and threshold based and showed that 
threshold of 0.3 gave us better performance with restart c of 0.9. We 
would like to predict the pathways, given a specific disease symptoms like 
cough, fever, headache etc. Human phenotype ontology (HPO) [90] 
provides symptoms data for different diseases integrating the data in our 
system will be a direction worth exploring and user can input symptoms 
and then it can predict the biological pathways, the proteins which are 
involved and it can easily identify what type of drugs is suitable for 
queried symptoms. 
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CHAPTER 4 
 
 
           NETPREDICTOR R PACKAGE 
 
 
4.1 INTRODUCTION 	
Social and biological systems can be represented by graphs where nodes 
represent individuals, biological experiments (protein, genes, etc.)  web 
users and so on.  Networks allow methods of graph theory to be applied 
to the task of predicting links. Link prediction predicts missing links in 
networks or links in future networks, it is also important for mining and 
analyzing the evolution of networks.  Link prediction problem is a long-
standing challenge in modern information science, and a lot of algorithms 
based on Markov chains and computer science community has proposed 
statistical models. The link prediction problem is usually defined in 
unipartite graphs.  The netpredictor package is developed to solve the 
problem of bipartite link prediction using Random walk with restart 
(RWR) and network based inference methods (NBI). We plan to integrate 
variety of other algorithms in near future. All of the code is developed in R, 
which also provides parallel execution modes. 
 
To compute the R package for prediction of missing links in a bipartite 
network/graph. The package provides utilities to compute missing links in 
a bipartite and well as unipartite network based on HeatS, Random walk 
with Restart (RWR), Network based inference (NBI) and combination of 
RWR and NBI . The package also allows one to compute Bipartite 
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network properties and well visualize communities and make a 
permutations test based prediction. With the advent of R open source 
statistical programming language [91] and gaining popularity of very useful 
“Shiny” package [92,93] that lets the programmers to create applications 
online, a new opportunity has been shown itself for creating netpredictor 
Shiny web app. 
4.2 LINK PREDICTION IN NETWORKS 
 
Link prediction is a new field of research in networks science and was 
first demonstrated by early 90’s by Nowell-Kleinberg [16, 17]. They tried 
to evaluate set of different similarity measures between vertices of a 
graph in order to predict unknown edges (links). They are classified into 
two categories: 
 Neighborhood based metrics and 
 Path based metrics 
In the netpredictor package we developed the methods  below for finding 
missing links in a network. 
 
4.2.1 LINK PREDICTION BY NEIGHBOURHOOD-BASED METRICS 
 
The following are the methods for neighbourhood-based metrics. Let 
Γ(x) be the set of neighbors of node x, and let |Γ(x)| be the number of 
neighbors of node x. 
• Common Neighbors (CN): CN is defined as the total number of 
nodes that two nodes x and y have common interaction with. More the 
number of links more significant the relation. It is defined using,  
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                                               CN (x, y) = Γ(x) Γ(y)4.1) 
• Jaccard Coefficient (JC) [18]: This is the extension of the common 
neighbors where it shows a proportion of nodes that are common between 
nodes x and y among all the nodes between x and y. The value is usually 
normalized between 0-1. It is defined using, 
 
                                    !" #. % = 	 ( ) ∩( +( ) ∪( +                          (4.2) 
• Cosine Similairity (CS): Cosine metric for two nodes x and y is defined 
as, 
    "- #, % = |((1)∩((3)|( ) .|((+)|                             (4.3) 
• Hub promoted Index (HP) [19] : It defines the topological overlap 
between nodesx and y. The links adjacent to hubs are assigned high 
scores since the denominator is of lower degree of nodes. It is defined 
using the following equation,   
 
                                          4 #, % = |((1)∩((3)|567	(|((1)|,|((3)|)                    (4.4) 
• Hub Depressed  Index   (HD):  This  is  similar  to  HP  index  but  
in  this  case  the denominator is determined by the higher degree of the 
nodes.  
                                                89 #, % = |((1)∩((3)|5:1	(|((1)|,|((3)|)                   (4.5) 
 
• Adamic Adar Index (AA) [20]: This index is similar to counting of 
common neigh- bors by assigning more weights to lower connected 
neighbors. It is defined as , 
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                                        ;;(#, %) = 		 <=>?	 |((@)|@∈(())∩((+)               (4.6) 
• Preferential Attachment (PA) [21]: The PA metric indicates the new 
links will be more likely to connect higher degree nodes than lower ones. 
Since it does not need to know the neighborhood of each node, so it has 
minimal computational complexity. It is given using the following 
equation as, 
 
                                              4; #, % = Γ # 	. |Γ(%)|                          (4.7) 
• Resource Allocation (RA) [22]: The Resource allocation index is 
similar to the adamic adar index which assigns more weights to lower 
connected neighbors but RA performs better with nodes having high 
average degrees. It defined by, 
 
                                    C; #, % = 	 <|((@)|@∈( ) ∩((+)                      (4.8) 
• Leicht-Holme-Nerman Index  (LHN)  [23]:  This  index  assigns  high  
similarity  to node pairs that have many common neighbours between 
them where |Γ(x)|.|Γ(y)| is the expected number of common neighbors. It 
is defined by ,   
                                    			!" #. % = 	 ( ) ∩( +( ) ∪( +                      (4.9) 
 
 4.2.2  LINK PREDICTION BY PATH-BASED METRICS 
 
Using path-based metrics one can compute paths between two nodes as 
similarity between node pairs. 
 Local Path (LP) [24]:  The local path based metric uses the path of 
length 2 and length 3. The metric uses the information of the nearest 
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neighbours and it also uses the information from the nodes within length 
of 3 distances from the current node. The paths of length 2 is more 
relevant that paths of length 3 so a parameter β is applied the value of 
which is close to 0. One can compute it using the Adjacency matrix 
using the equation given below,   
                                  LP = A2 + βA3                 (4.10) 
 Katz metric [25]:   Similarity measure based on all paths in a graph.  
This function counts all the paths between given pair of nodes with 
shorter paths counting more heavily. Parameters are exponential. 
|DEFℎ),+H  | is the set of all the paths between x and y with length  l  and β > 
0.  
                  IEFJ	 #, % = 	 KH. DEFℎ),+H = K; + KM; +	KN;N + ⋯	PHQ<             (4.11) 
 Geodesic similarity metric:  This function calculates similarity 
score for vertices based on the shortest paths between x and y. Its given 
using the equation below, 
                          RSTUSVWX #, % = 	 |VℎTYSFVF	DEFℎV|),+HPHQ<        (4.12)   
•  Hitting time and Commute time [26]:  Hitting time is 
calculated based on a random walk starts at a node x and iteratively 
moves to a neighbor of x chosen uniformly at random. The hitting time 
Hx,y from x to y is the expected number of steps required for a random 
walk starting at x to reach y. Since this metric is not symmetric, for 
undirected graphs the commute time, Cx,y = Hx,y + Hy,x can be used. 
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• Random Walk with Restart [26–28]: Random walk is a useful 
mathematical framework that provides a systematic way to measure 
importance of nodes in a network. The most widely known is the 
PageRank algorithm [29]. PageRank, developed for ranking web pages, 
measures page clicks of hypothetical web surfers who randomly click 
hyperlinks in the network of webpages. Since it is possible for the surfer 
to be trapped in a dead-end webpage that does not have any outgoing 
link, at each time step the surfer may jump to a random webpage with 
a probability c. Interestingly, this formulation also provides a simple way 
to define a random walk-based “distance” from a node a (or a set of nodes) 
to every other node, namely by allowing the random walkers to jump only 
to the source node a (or the source set of nodes) and restart from there. 
As a result, it is more likely to find the random walker at the vicinity of 
the source node than at a distant part of the network, and thus we are 
able to estimate the relevance (closeness) of each node with respect to the 
source node. The prediction method applies this idea to identify drugs 
and targets that are relevant to a set given set of drugs and targets. 
Consider an undirected, unweighted network G = (V, E),where  V     is the 
set of nodes and E is the set of links.  For each pair of nodes a,bV we 
can assign a proximity score by executing the following procedure: 
– we start a random walker from a. 
– At each time step, with the probability 1 - c, the walker walks to 
one of the neighbors, b, according to the transition value matrix Z[\ =	]^_`^  where -[\ is the adjacency matrix of the network and (-[\	equals 1  if 
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node a and b are connected, 0 otherwise ) I[ denotes  the degree of a. 
– With probability c , the walker goes back to a. 
– After many time steps the probability of finding the random walker 
at node x converges to the steady-state probability which is our 
proximity score -[→).  
 
The random walk with restart, whose updating equation is shown as 
follows: 
                                            pt+1  = (1-c)WT pt + cp0                              (4.13) 
Keep updating p until convergence; the stationary distribution vector p 
can meet, 
                                       pt = (1 − c)(I − cW T )−1p0                   (4.14)  
4.3 INSTALLATION 
 
A stable tested version of from github using the devtools package.  
Installing the package from github is given below, 
 
 
4.4 USING NETPREDICTOR STANDALONE R PACKAGE 
One can look at the properties,  which  can be calculated on unipartite 
graphs. 
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require(igraph) 
require(netpredictor) 
 
g1 <- upgrade_graph(erdos.renyi.game(100, 
1/100)) V(g1)$name <- seq(1,100,1) 
score_mat <- unetSim(g1,"aa") 
head(which(score_mat!=0, arr.ind = T)) 
 
## Common neighbors vertex similarity 
score_mat <- unetSim(g1,"cn") 
head(which(score_mat!=0, arr.ind = T)) 
 
## Jaccard Index similarity 
score_mat <- 
unetSim(g1,"jc") 
 
## Dice similarity 
score_mat <- unetSim(g1,"dice") 
 
## Katz Index similarity 
score_mat <- 
unetSim(g1,"katz") 
 
## Geodesic distance vertex similarity 
score_mat <- unetSim(g1,"dist") 
 
## Cosine vertex similarity/ Salton index 
score_mat <- unetSim(g1,"cosine") 
 
## Preferential attachment vertex similarity 
score_mat <- unetSim(g1,"pa") 
 
## Local Paths Index 
## This function counts the number of two-paths and 
## three-paths between 
nodes. score_lpsim <- 
unetSim(g1,"lp") 
 
## Hub promoted Index 
## This measures assigns higher scores to links adjacent to hubs 
## (high degree nodes). It counts common neighbors of two vertices 
## and weights the result. 
score_hpsim <- 
unetSim(g1,"hpi") 
 
## Similarity measure based on resource allocation process 
## (number of common neighbours weighted by the inverse of degrees) 
score_hpsim <- unetSim(g1,"ra") 
 
Next we look at the properties,  which can be calculated on bipartite 
graphs. 
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Next, we will use the different methods to predict links. Here we have shown 
examples based on drug target prediction. With the growing understanding 
of complex diseases, the focus of drug discovery has shifted away from “one 
target, one drug” model, to a new “multi-target, multi-drug” model. 
Predicting potential drug-target interactions from heterogeneous 
biological data is critical not only for better understanding of the various 
interactions and biological processes, but also for the development of 
novel drugs and the improvement of human medicines. To predict 
polypharmacology people use bayesian methods, SVM and Random Forest 
models, but in all of those algorithms the methods depends on labelled 
data to predict unknown links. Network based approaches does not rely 
on labelled data . Two of the algorihtms implemented in this package 
Random walk based Restart (RWR) and Network based Inference (NBI) to do 
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it. For performing RWR we used Drug target network, which is a bipartite 
graph in which every links connects drugs to proteins. 
 
 
In this example we attempt to use the dataseed file,  w h i ch  contains the 
pairs relations between targets and drugs. This can be useful when one 
is trying to investigate relations for a specific set of relations. The Drug 
names and proteins names should be included in the adjacency matrix 
when one uses the file option to provide dataseed. In the dataseed file 
the first column contains the proteins names and the second column the 
drug names. Ouput is a matrix of unique drugs against the number of 
targets in the adjacency matrix. 
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In this next example we will see how we can plot the significant 
communities of drugs from the final RWR computed matrix. For 
community detection we used the walktrap algorithm [13], which places 
nodes into communities based on neighborhood similarity from short 
random walks. We also input a list of drugs as vector and retrieve top 10 
interactions for each of those drugs. In this package after getting the 
results one can easily write the results in GML format for visualization in 
Gephi or cytoscape. It also support export to GEXF format (Gephi specific 
file format). Below shows the example of exporting to GML format. 
 
Drug Pnames score Type 
D00014 hsa2936 0.396969 True Interaction 
D00014 hsa2950 0.3973772 True Interaction 
D00014 hsa1719 0.0011479 Predicted Interaction 
D00014 hsa55312 0.0010483 Predicted Interaction 
D00014 hsa7172 0.0010385 Predicted Interaction 
D00014 hsa4128 0.0009746 Predicted Interaction 
 
    Table 4.1: Table shows the example of drug target interactions 
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Select a druglist to get the results for each of the drugs. 
 
 
The net.perf function samples and removes links from the adjacency matrix 
and predicts them and calculates area under accumulation curve, AUC, 
BEDROC (bdr), and Enrich- ment factor (EF). The area under the receiver 
operating characteristic (ROC) curve (AUC) is widely used metric for 
evaluation of predictive models.  The advantage of using AUC is that it is 
bounded, between 0 to 1 with 0.5 corresponding to random prediction. 
But AUC method has been critized in cheminformatics based virtual 
screening methods because it is not sensitive to early recognition 
compounds.  The EF tries to solve early recognition problem but it is 
dependent on the ratio of actives to inactives and the choice of subset X 
(fraction of active and inactive set). To try and overcome these limitations 
numerous other evaluation methods, such as robust initial enhancement 
(RIE) [10] and Boltzmann-enhanced discrimination of ROC (BEDROC) have 
been proposed [11]. Sheridan et al. developed an exponential weighted 
scoring scheme RIE which gives heavier weight in “early recognized” hits. 
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The BEDROC is constructed on top of RIE by, in essence, forcing the 
RIE to be bounded by 0 and 1, avoiding the dependence on the 
active/inactive ratio. In the example below we remove 50 links and 
repredict those links. While re-predicting them we calculate performance 
metrics like AUC, bedroc and enrichment factor. As the number of links 
(re- links) increases the performance of prediction drops. ’Calgo’ option uses 
different algorithms like NBI,RWR and netcombo. 
 
In 2010 Zhou et al. [], proposed a recommendation method based on the 
bipartite network projection technique implementing the concept of 
resources transfer within the network. The method developed here is 
based on Alaimo etal.[32]. The example given below one can use both the 
methods, using similarity matrices or  simply use heatS equation with the 
adjacency matrix. The nbiNet function is developed to perform the 
prediction. 
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Type AUAC AUC AUCTOP BECROC EFC 
RWR 0.932 0.976 0.606 0.520 9.206 
NBI 0.923 0.976 0.676 0.500 5.468 
NetCombo 0.936 0.976 0.602 0.520 9.087 
 
         Table 4.2: Results network performance using all the algorithms. 
 
I can also compute performance metrics using different algorithms like 
NBI, RWR and netcombo (fusion of results of NBI and RWR) to get auac 
auc, auctop, bdr and ef so that one can compare the performance using 
different algorithms. 
 
To calculate the significance of an interaction, I first compute the 
association score between drug a target and we want to found out 
whether the predicted association score is significant or not. We make 
1000 permutations of the association matrix and similarity matrix and 
compute NBI scores for 1000 random matrices and then we used a 
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normal distribution to calculate p-value. Then I convert the original 
compute score to an associated Z-score. Once the Z-score is found the 
probability that the value could be less the Z-score is found using the 
pnorm command.  Also for a two sided test we need to multiply the
result by two. Box  below gives an idea how we can achieve this.  We can 
create a significant network based on these significant associations found. 
The example give below shows the computation using network-based 
inference for 1000 permutations. 
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4.5 USING NETPREDICTOR R SHINY WEB APPLICATION 
The interface is consisted of two parts; web interface and web server. Both 
of these components are controlled by the code that is written within the 
framework of Shiny application in R. The building block of Shiny package 
is based on reactive programming. Since the ma- jor task of the web-
based  application is to get the inputs and produce outputs, the whole 
programming language is designed in a reactive programming approach 
so that a change in any input instantly change the end result. The Shiny 
application automatically updates the data tables and graphs in real-
time.  This is an advantage for the web applications that rely on user 
inputs. The shiny procedure can provide different outputs without the 
need to refresh the web page. Within the shiny package, ordinary 
controllers or widgets are provided for ease of use of application 
programmers. Many of the procedures like uploading files and refreshing 
the page for drawing new plots and tables are provided automatically. 
Websockets are exclusively important in situations where there is constant 
back and forth dialogue or data exchange between the clients and 
servers. The communication between the client and server is done over 
the normal TCP connection. The bulk of live data traffic that is needed for 
many of web applications (i.e. online games) between the browser and the 
server is facilitated over the websockets protocol. This protocol operates 
separately and only handshake between the client and server is done 
over the HTTP protocol. The duplex connection is open all the time and 
therefore the authentication is not needed when exchange is done. Figure 
		 79	
2.1 shows the web framework architecture for R shiny Web app. 
In order for a Shiny app to execute, we have to create a Shiny server 
installed in linux or CentOS. Shiny follows a pre-defined way to write R 
scripts. It consists of server.R and ui.R, which need to be in same 
directory location. If a developer want to customize the user interface 
shiny can also integrate additional CSS and JavaScript within the web 
application. The netpredictor shiny app is available at 
https://github.com/abhik1368/Shiny_NetPredictor . 
		
 
Figure 4.1: Diagram showing web architecture of NetPredictor Shiny 
app. 
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4.6 DESCRIPTION 
 
4.5.1 LOADING DATA 
 
One can load their own data or can use the given sample datasets given 
in the software. For the custom dataset option one needs to upload 
bipartite adjacency matrix along with the drug similarity matrix and 
protein sequence matrix. From the given datasets - enzyme, GPCR, Ion 
Channel and Nuclear Receptor in the application one can load the data 
and set the parameters for the given algorithms and start computations. 
Figure 4.2 shows the start page. 
 
4.5.2 RESULTS 
 
Once the data is loaded in the workspace and prediction button is pressed 
it instantly shows up network properties of the bipartite network in 
network properties tab and the predicted results of the given algorithm 
used. The results are easily downloadable as a csv file. It also shows up 
the interactive network plot it comes with true and predicted interactions 
in the network. The network can be downloaded as GML file. 
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Figure 4.2: Diagram starting page of NetPredictor Shiny app. 
 
 
Figure 4.3: Diagram showing results page of NetPredictor Shiny app. 
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Figure 4.4: Diagram shows network plot page NetPredictor Shiny app. 
 
 
4.5.3 ADVANCED ANALYSIS 
 
In the advanced analysis tab one can compute the different statistical 
metrics of your given data for three different algorithms NBI,RWR and 
NetCombo with given set of parameters. This can easily identify the 
performance of the network algorithms on your data.  Figure 4.5 shows 
the advanced analysis tab. A user can run number of times the 
algorithms with different sets of parameter settings. Two parameters are 
provided i.e removing the random links from a network with drugs 
having more than given frequency of targets. If the frequency of the 
targets is select as 0 then all the drug target relations are selected and 
if it is 2 only those drugs having more than 2 targets links will be 
removed from those drugs. The permutation testing can be also 
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performed using this tool. The method usually computes significant 
relations based on the number of random permutations with the original 
predicted matrix. One can select the significance level and get the results 
with significance level less than that given value. Figure 4.6 shows the 
results of prediction. 
 
 
Figure 4.5: Diagram shows advanced analysis page NetPredictor 
Shiny app. 
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Figure 4.6: Diagram shows Random permutations results page    
               NetPredictor Shiny app. 
 
CONLCUSION  
The netpredictor standalone package and shiny application helps in 
identification of missing links in bipartite and unipartite network. This 
application is not useful for biomedical domain but it can also be used in 
searching links in social informatics. The standalone is built using R and the 
web platform is built using R Shiny web, which integrates packages like 
shinythemes, shinysky, data.tables.js, vis.js, d3.js, gridster.js, igraph and 
reshape2. 
 
		 85	
 
 
CHAPTER 5 
 
FUTURE WORK AND SUMMARY 
 
5.1 Future Work 
Understanding polypharmacology is a critical problem in drug discovery 
especially of-class target polypharmacology which causes adverse effects and 
side effects. Random walk with restart has lot of potential in understanding of 
target-mediated effects and also will be useful for drug-repurposing 
applications. Other major areas where it can be used is in prioritization of 
candidate genes for various diseases, metabolic pathways, prediction of 
disease associated microRNAs, clustering of proteins based on protein-protein 
interactions, image segmentation and etc. 
5.2 Conclusion 
In this study, I examined the method of link prediction. Although the link 
prediction is not a new problem in informatics but it seems that the traditional 
methods have not been up with the recent development network science. One of 
biggest challenges in link prediction is using multi-dimensional and multi-
partite networks where each of the link associations could have a different 
meaning and consists of different classes of nodes in it respectively. For 
example, multiple relations can exist between a ligand and target, a drug binds 
to a protein target based on its activity, whether it is an inducer, activator or 
enhancer, it can show adverse events. In my opinion in-depth understanding, 
complex networks (example making use of the modular structure of the network 
and hierarchical organization) can help in the development of advanced link 
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prediction algorithms. In this work, I developed a novel technique of random 
walk with a restart to predict drug-target interactions and identification of 
metabolic pathways of a given disease condition. Studying drug target 
interaction using traditional techniques is time-consuming and needs some 
special software packages to understand potential interactions. However, we 
can reduce the time gap by using methods like random walk with restart to 
rank the interactions and then study significant interactions using special 
cheminformatics tools. Chapter 1 introduced some traditional ways of doing 
ligand based and target-based methods to study drug target interactions and 
introduced some link prediction methods in using neighborhood based and 
path-based metrics. Focusing on the path-based metrics, I introduced the 
concept of random walk with restart and how we can use to predict missing 
links in a network. Chapter 2 introduces random walk restart in heterogeneous 
drug target network where we integrated drug-drug chemical similarity 
network, drug-target network and target-target network based on protein 
sequence similarity. I thought using different chemical features would result in 
a different ranking of targets, but surprisingly I observed using four different 
chemical features and optimizing a parameter η I achieved similar kind of 
results, which indicated using commercial or open source chemical similarity 
fingerprints for drug network the results doesn't vary much. Next, Chapter 3 
focuses on the using RWR to a four-layered (disease layer, protein layer, protein 
complexes layer and the protein-biological pathway layer) network for 
identification Biological pathways related to a query disease. The protein layer 
consists of a ppi network from a tissue based gene expression, which connects 
to disease layer via association of disease tissues associations. Based on the 
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query disease a given tissue is selected, and a particular protein-protein 
network is loaded and then we generate the full four-layered network and get 
the pathway predictions. We tested two different types of disease similarity 
network using K-Nearest Neighbor and similarity threshold based and showed 
that threshold of 0.3 gave us better performance with restart c of 0.9.  
In chapter 4 we introduce the netpredictor package to compute properties and 
predict links in a bipartite and unipartite network. I also develop some 
functions to compute node centrality measures in two-mode networks using 
bipartite network projection. I have developed three algorithms to predict 
missing links in a bipartite network namely NBI, HeatS and RWR. Apart from 
using a standalone package a web-based software developed in R shiny. Shiny 
is a platform to develop web-based applications using R. The matrix 
computations are done using the Revolutions Analytics parallel package and 
later on upgraded to Revolutions R open which includes intel math kernel 
(MKL) which provides BLAS and LAPACK library functions. For Mac OSx users, 
it uses ATLAS blas library functions. MKL uses, as many parallel threads as 
there are number of cores. The shiny web app uses some javascript libraries 
like bootstrap.js for creating navbars and tabs, vis.js for developing the 
interactive network based visualization, data.tables.js for generating tables, 
gridster.js for moving the network properties grid around the page. It uses some 
packages like shinythemes, shinyBS, shinyjs, shinysky for look and feel of the 
web application. 
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